• News
  • Technology
  • Culture
  • Entertainment
  • Sport
  • Travel
  • Music
  • More
    • Politics
    • Lifestyle
    • TV
    • Games
Friday, March 24, 2023
  • Login
No Result
View All Result
NEWSLETTER
FINCHANNEL
  • Home
  • Business
    • BANKS
      • GeoBanks
    • Finance
    • Insurance
    • Markets
    • Pharmacy
    • Press Releases
    • RealEstate
    • RealEstate
    • Finance
    • Insurance
    • Banks
      • GeoBanks
    • Markets
    • Press Releases
    • Personal Finance
  • World
    • America
    • Europe
    • Georgia
      • Media
    • Ukraine
    • Europe
    • Georgia
      • Media
    • Ukraine
    • Americas
    • UK local news
  • Travel
    • Hotels in Georgia
    • Tours in Georgia
  • Videos
    • Promos
    • Soundslides
    • TheClinics
    • TheHoteliers
    • TheUniversities
    • TheHoteliers
    • TheClinics
    • TheUniversities
    • BestWorkplaces
    • Soundslides
    • Promos
    • Banking Forum
      • Promos
      • Soundslides
      • TheClinics
      • TheHoteliers
      • TheUniversities
  • Opinion
    • Editorial
      • Analysis
      • GORBI
      • OP-ED
      • VISA Editorial
    • Analysis
    • Gorbi
    • Book reviews
  • Tech
  • Interview
  • People
    • CityLife
    • Health & Beauty
      • Coronavirus
    • LifeStyle
    • Employment
      • MyCareer
    • Education
    • Media
    • Celebrities
  • Oil&Auto
    • Auto
    • Energy
  • EN
    • EN
    • GE
  • Home
  • Business
    • BANKS
      • GeoBanks
    • Finance
    • Insurance
    • Markets
    • Pharmacy
    • Press Releases
    • RealEstate
    • RealEstate
    • Finance
    • Insurance
    • Banks
      • GeoBanks
    • Markets
    • Press Releases
    • Personal Finance
  • World
    • America
    • Europe
    • Georgia
      • Media
    • Ukraine
    • Europe
    • Georgia
      • Media
    • Ukraine
    • Americas
    • UK local news
  • Travel
    • Hotels in Georgia
    • Tours in Georgia
  • Videos
    • Promos
    • Soundslides
    • TheClinics
    • TheHoteliers
    • TheUniversities
    • TheHoteliers
    • TheClinics
    • TheUniversities
    • BestWorkplaces
    • Soundslides
    • Promos
    • Banking Forum
      • Promos
      • Soundslides
      • TheClinics
      • TheHoteliers
      • TheUniversities
  • Opinion
    • Editorial
      • Analysis
      • GORBI
      • OP-ED
      • VISA Editorial
    • Analysis
    • Gorbi
    • Book reviews
  • Tech
  • Interview
  • People
    • CityLife
    • Health & Beauty
      • Coronavirus
    • LifeStyle
    • Employment
      • MyCareer
    • Education
    • Media
    • Celebrities
  • Oil&Auto
    • Auto
    • Energy
  • EN
    • EN
    • GE
No Result
View All Result
FINCHANNEL
No Result
View All Result
ADVERTISEMENT
Home Business Pharmacy

U.S. Food and Drug Administration Approves Gilead’s Second TAF-Based Single Tablet Regimen Odefsey

by The FINANCIAL
March 2, 2016
in Pharmacy
0
Share on FacebookShare on Twitter

The FINANCIAL — Gilead Sciences, Inc. on March 1 announced that the U.S. Food and Drug Administration (FDA) has approved Odefsey (emtricitabine 200 mg/rilpivirine 25 mg/tenofovir alafenamide 25 mg or R/F/TAF) for the treatment of HIV-1 infection in certain patients.

Emtricitabine and tenofovir alafenamide are from Gilead Sciences and rilpivirine is from Janssen Sciences Ireland UC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen). Odefsey is Gilead’s second TAF-based regimen to receive FDA approval and represents the smallest pill of any single tablet regimen for the treatment of HIV.

Odefsey is indicated as a complete regimen for the treatment of HIV-1 infection in patients 12 years of age and older who have no antiretroviral treatment history and HIV-1 RNA levels less than or equal to 100,000 copies per mL. Odefsey is also indicated as replacement for a stable antiretroviral regimen in those who are virologically-suppressed (HIV-1 RNA less than 50 copies per mL) for at least six months with no history of treatment failure and no known substitutions associated with resistance to the individual components of Odefsey. No dosage adjustment of Odefsey is required in patients with estimated creatinine clearance greater than or equal to 30 mL per minute, according to Gilead.

RelatedPosts

Roche ranked the most sustainable healthcare company in the DJSI

Gilead and Novo Nordisk announced new data from proof-of-concept trial in NASH

Metagenomi closes USD 65 million Series A financing led by Leaps by Bayer and Humboldt Fund

Pharmaceutical industries join to promise fair access to COVID-19 medicines and vaccines

Odefsey has a boxed warning in its product label regarding the risks of lactic acidosis/severe hepatomegaly with steatosis, and post treatment acute exacerbation of hepatitis B. See below for important safety information.

TAF is a novel targeted prodrug of tenofovir that has demonstrated high antiviral efficacy similar to and at a dose less than one-tenth that of Gilead’s Viread (tenofovir disoproxil fumarate, TDF). TAF has also demonstrated improvement in surrogate laboratory markers of renal and bone safety as compared to TDF in clinical trials in combination with other antiretroviral agents. Data show that because TAF enters cells, including HIV-infected cells, more efficiently than TDF, it can be given at a much lower dose and there is 90 percent less tenofovir in the bloodstream.

“As people are living longer with HIV, there is an increasing need to develop new treatments that are tolerable and help address long-term health for patients,” said John C. Martin, PhD, Chairman and Chief Executive Officer, Gilead Sciences. “Odefsey’s safety, efficacy and tolerability profile offers a new treatment option to support the needs of a range of patients and represents Gilead’s commitment to innovation in the field of HIV.”

The approval is supported by a bioequivalence study demonstrating that Odefsey achieved similar drug levels of emtricitabine and TAF in the blood as Genvoya (elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg or E/C/F/TAF) and similar drug levels of rilpivirine as Edurant (rilpivirine 25 mg). The safety, efficacy and tolerability of Odefsey is supported by clinical studies of rilpivirine-based therapy (administered as R+F/TDF or R/F/TDF) and F/TAF-based therapy (administered as E/C/F/TAF) in a range of patients with HIV, including treatment-naïve adults and adolescents, virologically suppressed adults who switched from PI-, NNRTI- and INSTI-based regimens and virologically suppressed adults with mild-to-moderate renal impairment.

The Odefsey approval is part of an ongoing development and commercialization agreement between Gilead and Janssen, first established in 2009. Under this agreement, Gilead is responsible for the manufacturing, registration, distribution and commercialization of the product in most countries, while Janssen will distribute it in approximately 17 markets and have co-detailing rights in several key markets, including the United States. The original agreement was established for the development and commercialization of Complera®, marketed as Eviplera® in the European Union, and expanded in 2014 to include Odefsey.

Odefsey does not cure HIV infection or AIDS.

Patient Assistance Programs

Gilead’s U.S. Advancing Access program provides assistance to appropriate patients in the United States who are uninsured, underinsured or who need financial assistance to pay for their medications, including Odefsey.

The program offers information and assistance for patients, including:

Access to agents who can provide information related to coverage and insurance-related questions.

The Advancing Access Copay Coupon Program, which provides co-pay assistance for eligible patients with private insurance who need assistance paying for out-of-pocket medication costs.

The Advancing Access Patient Assistance Program and Truvada® Medication Assistance Program, which will provide Gilead medications at no charge for eligible patients with no other insurance options.

Additionally, Gilead is working closely with the ADAP Crisis Task Force, as the company has done for each of its other HIV medications, to provide discounts to state AIDS Drug Assistance Programs (ADAPs) that will help ensure access to Odefsey for patients who receive medications through these programs.

 

ADVERTISEMENT
The FINANCIAL

The FINANCIAL

Related Posts

Roche ranked the most sustainable healthcare company in the DJSI
Pharmacy

Roche ranked the most sustainable healthcare company in the DJSI

by The FINANCIAL
November 16, 2020
0

The FINANCIAL -- For the eleventh time, Roche has been recognised as the most sustainable company in the Pharmaceuticals index...

Read more
Gilead and Novo Nordisk announced new data from proof-of-concept trial in NASH

Gilead and Novo Nordisk announced new data from proof-of-concept trial in NASH

November 16, 2020
Metagenomi closes USD 65 million Series A financing led by Leaps by Bayer and Humboldt Fund

Metagenomi closes USD 65 million Series A financing led by Leaps by Bayer and Humboldt Fund

November 12, 2020
Pharmaceutical industries join to promise fair access to COVID-19 medicines and vaccines

Pharmaceutical industries join to promise fair access to COVID-19 medicines and vaccines

November 12, 2020
Next Post

WHO outlines ways to prevent and mitigate childhood hearing loss

Please login to join discussion
ADVERTISEMENT
  • Trending
  • Comments
  • Latest
EasyJet to fly to London from Stockholm Arlanda

The London Diplomatic List, Addresses, Contacts & Working Hours

January 23, 2023
How to Check KRA Pin Using ID Number

How to Check KRA Pin Using ID Number

June 25, 2018
How to Manage an Employee Who’s Having a Personal Crisis

5 Assets To Store Your Wealth During Times Of Crisis

September 22, 2022
Russian issue: State Sponsors of Terrorism, U.S. State Department

Americans’ Favorable Rating of Russia Sinks to New Low of 9%

March 14, 2023
UK Government has ordered to freeze assets of additional 300 persons related to ISIL and AL-QAIDA

UK Government has ordered to freeze assets of additional 300 persons related to ISIL and AL-QAIDA

October 3, 2020
Maximizing Your Returns: How to Choose the Right Mutual Fund‍

Maximizing Your Returns: How to Choose the Right Mutual Fund‍

March 24, 2023
Protected: 6 Things You Should Know About a Master’s in Accountancy

Protected: 6 Things You Should Know About a Master’s in Accountancy

March 22, 2023
How Custom CRM Can Help Businesses: Perks, Hurdles, and Your Ultimate Game Plan

How Custom CRM Can Help Businesses: Perks, Hurdles, and Your Ultimate Game Plan

March 21, 2023
UK boosts support for International Criminal Court

UK boosts support for International Criminal Court

March 20, 2023
Children whose mothers use marijuana may try it at a younger age

By 2025, the estimated marijuana retail sales may generate up to 15 billion U.S. dollars in sales

March 20, 2023

Popular Last 24h

  • How to Check KRA Pin Using ID Number

    How to Check KRA Pin Using ID Number

    0 shares
    Share 0 Tweet 0
  • Kvaratskhelia Football Dynasty: Mamia, Badri, Khvicha and Tornike

    0 shares
    Share 0 Tweet 0
  • The London Diplomatic List, Addresses, Contacts & Working Hours

    0 shares
    Share 0 Tweet 0
  • 5 Assets To Store Your Wealth During Times Of Crisis

    0 shares
    Share 0 Tweet 0
  • Maximizing Your Returns: How to Choose the Right Mutual Fund‍

    0 shares
    Share 0 Tweet 0
  • YouPorn made TikTok like app for adults

    0 shares
    Share 0 Tweet 0
  • Nearly 40,000 Victims Receive Over $115M in Compensation for Fraud Schemes Processed by MoneyGram

    0 shares
    Share 0 Tweet 0

LATEST POSTS

Maximizing Your Returns: How to Choose the Right Mutual Fund‍

Maximizing Your Returns: How to Choose the Right Mutual Fund‍

March 24, 2023
Protected: 6 Things You Should Know About a Master’s in Accountancy

Protected: 6 Things You Should Know About a Master’s in Accountancy

March 22, 2023
How Custom CRM Can Help Businesses: Perks, Hurdles, and Your Ultimate Game Plan

How Custom CRM Can Help Businesses: Perks, Hurdles, and Your Ultimate Game Plan

March 21, 2023
UK boosts support for International Criminal Court

UK boosts support for International Criminal Court

March 20, 2023
Children whose mothers use marijuana may try it at a younger age

By 2025, the estimated marijuana retail sales may generate up to 15 billion U.S. dollars in sales

March 20, 2023
New Study of Coronavirus Variants Predicts Virus Evolving to Escape Current Vaccines, Treatments

SARS-CoV-2 infection weakens immune-cell response to vaccination

March 20, 2023
107,735 Americans died between August 2021 and August 2022 from drug poisonings

107,735 Americans died between August 2021 and August 2022 from drug poisonings

March 20, 2023
Protected: Maximizing Your Returns: How to Choose the Right Mutual Fund‍

Protected: Maximizing Your Returns: How to Choose the Right Mutual Fund‍

March 20, 2023
Women imitate masculine traits to be taken seriously as gamers

Online Live Casinos with Huge Earnings

March 16, 2023
Local manufacturing is one of the primary factors that can guarantee the stability of any country

Local manufacturing is one of the primary factors that can guarantee the stability of any country

March 16, 2023

LATEST INTERVIEWS

‘Russia cannot be treated as a reasonable and reliable trade partner

‘Russia cannot be treated as a reasonable and reliable trade partner

by The FINANCIAL
February 13, 2023
0

We should increase our joint efforts to assist the growing tech sector here in Georgia

We should increase our joint efforts to assist the growing tech sector here in Georgia

by The FINANCIAL
February 13, 2023
0

‘Georgia has much to offer to UK investors

‘Georgia has much to offer to UK investors

by The FINANCIAL
February 13, 2023
0

‘The best way for the Georgian economy to prosper is to join the EU

‘The best way for the Georgian economy to prosper is to join the EU

by The FINANCIAL
February 13, 2023
0

‘The Kremlin wants Georgia to fail or abandon its European path

‘The Kremlin wants Georgia to fail or abandon its European path

by The FINANCIAL
February 13, 2023
0

Russian Patriarch Kirill Says Dying In Ukraine ‘Washes Away All Sins’

Interview: Why Putin Might Prefer A Stalemate To Going Nuclear On Ukraine

by The FINANCIAL
October 22, 2022
0

Kvaratskhelia Football Dynasty: Mamia, Badri, Khvicha and Tornike

Kvaratskhelia Football Dynasty: Mamia, Badri, Khvicha and Tornike

by Tengiz Pachkoria
August 11, 2022
0

“Green business is a key instrument to support business development in a sustainable way”

“Green business is a key instrument to support business development in a sustainable way”

by The FINANCIAL
July 27, 2022
0

Newsletter

ADVERTISEMENT

GET IN TOUCH

E-mail your company news at:

news (at) financial.ge Letters to the Editor: editor (at) finchannel.com

Local Marketing contact:

(+99532) 2252 275 | 76 EXT: 1 (+995 558) 03 03 03 (mobile) marketing (at) finchannel.com

Requests from abroad:

(+99532) 2252 275 | 76 EXT: 7 (+995599) 96 52 52 Email: zviadi (@) finchannel.com Contact video editor: E-mail: video (at) financial.ge

Postal address: 17 Mtskheta str. Tbilisi, Georgia 0179 The FINANCIAL

RESOURCE

  • Work at the FINANCIAL
  • ePaper
  • Advertise in The FINANCIAL
  • Access ePaper
  • Guest posts
  • Contributed articles
  • AmericanStockNews
  • Coupon Codes
  • GLOSSY MAG
American Culture Center
ACC Partner

GUIDEBOOK

  • Meet our team
  • Invest in Georgia
  • Become contributor
  • Archive

FOLLOW US

  • Facebook
  • Twitter
  • Google+
  • Youtube
No Result
View All Result
  • Home
  • Business
    • BANKS
      • GeoBanks
    • Finance
    • Insurance
    • Markets
    • Pharmacy
    • Press Releases
    • RealEstate
    • RealEstate
    • Finance
    • Insurance
    • Banks
      • GeoBanks
    • Markets
    • Press Releases
    • Personal Finance
  • World
    • America
    • Europe
    • Georgia
      • Media
    • Ukraine
    • Europe
    • Georgia
      • Media
    • Ukraine
    • Americas
    • UK local news
  • Travel
    • Hotels in Georgia
    • Tours in Georgia
  • Videos
    • Promos
    • Soundslides
    • TheClinics
    • TheHoteliers
    • TheUniversities
    • TheHoteliers
    • TheClinics
    • TheUniversities
    • BestWorkplaces
    • Soundslides
    • Promos
    • Banking Forum
      • Promos
      • Soundslides
      • TheClinics
      • TheHoteliers
      • TheUniversities
  • Opinion
    • Editorial
      • Analysis
      • GORBI
      • OP-ED
      • VISA Editorial
    • Analysis
    • Gorbi
    • Book reviews
  • Tech
  • Interview
  • People
    • CityLife
    • Health & Beauty
      • Coronavirus
    • LifeStyle
    • Employment
      • MyCareer
    • Education
    • Media
    • Celebrities
  • Oil&Auto
    • Auto
    • Energy
  • EN
    • EN
    • GE

© 2023 JNews - Premium WordPress news & magazine theme by Jegtheme.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
This website uses cookies. By continuing to use this website you are giving consent to cookies being used. Visit our Privacy and Cookie Policy.